𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Gemtuzumab ozogamicin as first-line treatment in patients aged 70 years or older with acute myeloid leukemia

✍ Scribed by Wassim McHayleh; Kenneth Foon; Robert Redner; Rajesh Sehgal; Anastasios Raptis; Mounzer Agha; The Minh Luong; James J. Schlesselman; Michael Boyiadzis

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
159 KB
Volume
116
Category
Article
ISSN
0008-543X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of intensive chemotherapy in 998
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: : Predictive prognostic models for outcome
✍ Hagop Kantarjian; Susan O'Brien; Jorge Cortes; Francis Giles; Stefan Faderl; Eli 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract ## BACKGROUND Elderly patients (age ≥ 65 years) with acute myeloid leukemia (AML) generally have a poor prognosis. AML‐type therapy results are often derived from studies in younger patients and may not apply to elderly AML. Many investigators and oncologists advocate, at times, only s

Phase 2 trial of docetaxel and gefitinib
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older
✍ George R. Simon; Martine Extermann; Alberto Chiappori; Charles C. Williams; Mube 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 181 KB 👁 2 views

## Abstract ## BACKGROUND This is a phase 2 study of chemotherapy‐naive patients, 70 years of age or older, with nonsmall‐cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overall survival (OS) and progress